Abstracts tagged "therapy and tumor necrosis factor (TNF)"

Abstract Number: 2875 • ACR/ARHP Annual Meeting 2015
Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Fabiola Atzeni¹, Antonio Carletto², Marco Sebastiani³, Valentina Panetta⁴, Fausto Salaffi⁵, Florenzo Iannone⁶, Elisa Gremese⁷, Marcello Govoni⁸, Antonio Marchesoni⁹, Roberto Gorla¹⁰, Roberta Ramonda¹¹, Pier Carlo Sarzi-Puttini¹², Gianfranco Ferraccioli⁷, Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy, ³SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ⁴L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁵Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁷Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁸Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ⁹Rheumatology Unit, Orthopedic Institute G. Pini, Milano, Italy, ¹⁰Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ¹¹Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ¹²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: The use of TNF inhibitors (TNFIs) has led to efficient control of the signs and symptoms of SpA and rheumatoid arthritis (RA), and significantly…
Abstract Number: 1291 • ACR/ARHP Annual Meeting 2013
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…